Phaseline

Companies › Scholar Rock

Scholar Rock: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apitegromab
Growth/differentiation factor 8 inhibitor
MSTNPhase 3Spinal Muscular Atrophy; Facioscapulohumeral Muscular DystrophyJun 2028
SRK-439
Activin A ligand trap
–Phase 1HealthyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07444294SRK-439Phase 1HealthyOtherDec 2026
NCT07435129ApitegromabPhase 2Facioscapulohumeral Muscular DystrophyNeurologyJun 2028
NCT07047144ApitegromabPhase 2Spinal Muscular AtrophyNeurologyNov 2028
NCT05626855ApitegromabPhase 3Spinal Muscular AtrophyNeurologyMay 2029

From the company's SEC filings

Cash and short-term investments of $414m on 2026-09-30; operating cash outflow about $314m a year; runway about 16 months at that burn, to Jan 2028; 0 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MSTN (1)

Companies with the same targets

Roche Regeneron Pharmaceuticals

Companies built like this

Ensysce Biosciences Cartesian Therapeutics Epygenix Shaanxi Micot Pharmaceutical Technology Harmony Biosciences Management

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.